文献速递急性肾损伤血液净化与透析

高容量腹膜透析急性肾损伤患者的万古霉素清除:前瞻性队列研究

Vancomycin Removal During High-Volume Peritoneal Dialysis in Acute Kidney Injury Patients: A Prospective Cohort Clinical Study.
PubMed 文献 · Kidney Int Rep · 2018-09-27

本研究前瞻性纳入10例接受高容量腹膜透析(HVPD)的急性肾损伤(AKI)患者,给予单次静脉万古霉素15-20 mg/kg,测定透析液及血药浓度。HVPD平均清除万古霉素21.7%±2.2%,腹膜清除率8.1±2.2 ml/min,血清半衰期71.2±24.7小时。结论认为HVPD可清除相当量万古霉素,18 mg/kg每48-72小时给药可达治疗浓度。

要点

  • HVPD对AKI患者万古霉素的平均清除率为21.7%±2.2%。
  • 血清万古霉素半衰期在HVPD期间为71.2±24.7小时。
  • 18 mg/kg每48-72小时给药可达治疗浓度。

核心结论

  • HVPD可清除相当量的万古霉素,在AKI合并脓毒症患者中需按18 mg/kg每48-72小时给药以达治疗浓度。

研究设计与样本

  • 前瞻性队列临床研究,10例AKI接受HVPD患者完成研究,单次静脉给予万古霉素15-20 mg/kg,透析前1小时给药,收集24小时透析液及给药后1、2、4、24小时血样,采用HPLC-荧光法测定浓度,按一室模型计算药代动力学。

主要发现

  • 研究日(第一天)平均万古霉素剂量为18.0±2.95 mg/kg(范围14.7-21.8 mg/kg)。
  • HVPD平均清除万古霉素百分比为21.7%±2.2%(范围16%-29%)。
  • 腹膜清除率为8.1±2.2 ml/min(范围5.3-12 ml/min)。
  • HVPD期间血清万古霉素半衰期为71.2±24.7小时(范围42-110小时)。
  • 最大血清浓度为26.2±3.5 mg/l,出现在万古霉素给药及HVPD开始后1小时;当MIC=1 mg/l时,所有患者AUC0-24/MIC比值≥400。

关键数值与推荐

  • 万古霉素给药剂量为15-20 mg/kg,研究日平均18.0±2.95 mg/kg。
  • HVPD平均清除百分比21.7%±2.2%,腹膜清除率8.1±2.2 ml/min,血清半衰期71.2±24.7小时。
  • 当MIC=1 mg/l时,所有患者AUC0-24/MIC≥400。
  • 推荐AKI接受HVPD患者万古霉素18 mg/kg每48-72小时给药。

临床怎么用

  • 对AKI接受HVPD的患者,可考虑万古霉素18 mg/kg每48-72小时给药,并根据血药浓度监测调整。
  • HVPD期间万古霉素半衰期明显延长,需关注药物蓄积风险。

局限性

  • 样本量仅10例,结果需更大样本验证。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Vancomycin pharmacokinetic data in patients with acute kidney injury (AKI) on high-volume peritoneal dialysis (HVPD) are lacking. The aims were to study the pharmacokinetics of i.v. vancomycin in patients with AKI treated by HVPD who received an i.v. dose of vancomycin (15-20 mg/kg), to determine the vancomycin removal, and to establish vancomycin dosing and evaluation pharmacokinetics target attainment achievement for the empirical treatment of patients with AKI treated by HVPD. METHODS: Vancomycin was administered 1 hour before dialysis start. Samples of all dialysate were collected for a 24-hour period. Blood samples were collected after 1, 2, 4, and 24 hours of therapy. Vancomycin concentrations were determined using a liquid chromatographic (high-performance liquid chromatography)-fluorescence method. Pharmacokinetic calculations were completed assuming a 1-compartment model. RESULTS: Ten patients completed the study. The mean vancomycin dose administered was 18.0 ± 2.95 mg/kg (14.7-21.8 mg/kg) on the day of study (first day) and the mean percentage of vancomycin removal by HVPD was 21.7% ± 2.2% (16%-29%). Peritoneal clearance was 8.1 ± 2.2 ml/min (5.3-12 ml/min). The serum vancomycin half-life was 71.2 ± 24.7 hours (42-110 hours) during HVPD session, the maximum serum concentration was 26.2 ± 3.5 mg/l, which occurred 1 hour after vancomycin administration and HVPD start. Area under the curve (AUC)0-24/minimum inhibitory concentration (MIC) ratio ≥400 was achieved in all patients when MIC = 1 mg/l was considered. CONCLUSION: HVPD removes considerable amounts of vancomycin in septic patients with AKI. Administration of 18 mg/kg vancomycin each 48 to 72 hours in patients with AKI undergoing HVPD was required to reach and maintain therapeutic concentrations.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Ponce D, Zamoner W, Freitas FM, et al. Vancomycin Removal During High-Volume Peritoneal Dialysis in Acute Kidney Injury Patients: A Prospective Cohort Clinical Study. Kidney Int Rep. 2018. PMID: 30596174. doi:10.1016/j.ekir.2018.09.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。